Health Care Archives - Page 28 of 478

2 minute read

Generic Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit Settlement

May 3, 2:43 PM

Amneal Pharmaceuticals settles $270 million opioid crisis agreement, offering cash and naloxone spray. Boosted by strong Q1 earnings, the company reaffirms fiscal guidance.

AMRX

2 minute read

Alignment Healthcare Is ‘Differentiated With Durable Long-Term Growth Trajectory’ In Challenging Medicare Advantage Environment: Analyst Says

By Vandana Singh

May 3, 2:02 PM

Alignment Healthcare earnings: EPS loss $(0.25), sales surge 43.1% to $628.6M, beats guidance. Health plan membership up 50.5% Y/Y. Q2 revenue guidance: $625M-$635M. FY 2024 sales raised to $2.495B-$2.525B. Expert outlook: Favorable Q1, stable cost trends.

ALHC

2 minute read

Newly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday – Read Here Why

By Vandana Singh

May 3, 1:11 PM

Preliminary results of AEON Biopharma's Phase 2 trial for chronic migraine treatment reveal no significant improvement over placebo. Despite anticipated reductions in monthly migraine days, statistical significance was not reached, prompting a review of development strategies and financial measures.

AEON

1 minute read

What’s Going On With Healthcare Logistics Giant Owens & Stock On Friday?

By Vandana Singh

May 3, 12:56 PM

Owens & Minor impresses with Q1 results: adjusted EPS of $0.19, and sales of $2.61B (up 4% Y/Y). Patient Direct revenue reaches $638M (up 5% Y/Y). CEO Edward Pesicka highlights growth strategies and reaffirms 2024 revenue guidance of $10.5-$10.9 billion and adjusted EPS of $1.40-$1.70.

OMI

2 minute read

Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio’s Bladder Cancer Combo Therapy

By Vandana Singh

May 3, 12:19 PM

Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expand BCG supply. FDA-approved Anktiva plus BCG for bladder cancer.

IBRX

2 minute read

Amgen Outlook Is Bright, Analyst Predict Obesity-Focused Drug Potential Will Drive Shareholder Value

By Vandana Singh

May 3, 11:24 AM

Amgen earnings beat estimates, and MariTide's promising Phase 2 results suggest significant differentiation from competitors.

AMGN

3 minute read

Benzinga’s ‘Stock Whisper’ Index: 5 Stocks Investors Secretly Monitor But Don’t Talk About Yet

By Chris Katje

May 3, 10:51 AM

The Benzinga Stock Whisper highlights five stocks each week that are seeing increased attention from readers and partners.

AMZN

2 minute read

Weigh Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro

By Vandana Singh

May 2, 4:01 PM

Reduced prices on Wegovy and Mounjaro at British pharmacies amid growing competition. Simple Online Pharmacy slashes Mounjaro starter doses to £149 from £179, catering to high demand.

LLY

2 minute read

Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation

By Vandana Singh

May 2, 3:49 PM

Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%.

REGN

2 minute read

Eye Disease-Focused Glaukos’ ‘Investor Interest Should Continue To Gain Momentum:’ Analyst

By Vandana Singh

May 2, 3:36 PM

Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%.

GKOS